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Abstract 
Epidemiological studies suggest that a single moderate-to-severe traumatic brain injury (TBI) is 
associated with an increased risk of neurodegenerative disease, including Alzheimer’s and 
Parkinson’s disease (AD and PD). Histopathological studies describe complex neurodegenerative 
pathologies in individuals exposed to single moderate-to-severe TBI or repetitive mild TBI, 
including chronic traumatic encephalopathy (CTE).  However, the clinicopathological links 
between TBI and post-traumatic neurodegenerative diseases such as AD, PD, and CTE remain 
poorly understood. Here we describe the methodology of the Late Effects of TBI (LETBI) study, 
whose goals are to characterize chronic post-traumatic neuropathology and to identify in vivo 
biomarkers of post-traumatic neurodegeneration. LETBI participants undergo extensive clinical 
evaluation using National Institutes of Health TBI Common Data Elements, proteomic and 
genomic analysis, structural and functional MRI, and prospective consent for brain donation. 
Selected brain specimens undergo ultra-high resolution ex vivo MRI and histopathological 
evaluation including whole mount analysis. Co-registration of ex vivo and in vivo MRI data 
enables identification of ex vivo lesions that were present during life. In vivo signatures of 
postmortem pathology are then correlated with cognitive and behavioral data to characterize the 
clinical phenotype(s) associated with pathological brain lesions.  We illustrate the study methods 
and demonstrate proof of concept for this approach by reporting results from the first LETBI 
participant, who despite the presence of multiple in vivo and ex vivo pathoanatomic lesions had 
normal cognition and was functionally independent until her mid-80s.  The LETBI project 
represents a multidisciplinary effort to characterize post-traumatic neuropathology and identify 
in vivo signatures of postmortem pathology in a prospective study. 
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Introduction 
Traumatic brain injury (TBI) may be associated with an increased risk of neurodegenerative 
disease, including Alzheimer’s disease (AD), Parkinson’s disease (PD), and chronic traumatic 
encephalopathy (CTE).1-5 However, these outcomes affect only a portion of long-term TBI 
survivors, and the pathogenesis, clinical phenotypes, and neuropathological signatures of post-
traumatic neurodegeneration are incompletely understood.6-8 Similarly, the mechanistic link 
between postmortem pathology and clinical symptoms is undefined.  Limited knowledge of the 
neurodegenerative sequelae of TBI has precluded the identification of in vivo biomarkers of TBI-
associated neurodegeneration, which impedes the development of targeted therapies.   
 Here, we describe the methods of a prospective, multi-institutional study, the Late Effects 
of TBI (LETBI) project, which aims to advance understanding of the behavioral characteristics, 
imaging biomarkers, pathophysiology and neuropathological signatures associated with post-
traumatic conditions that follow a single moderate or severe TBI or multiple mild TBI.  The 
conceptual basis for the LETBI project is that prospective acquisition and multimodal integration 
of neurobehavioral, neuroimaging, and neuropathological data in large, well-characterized 
samples are essential for advancing scientific knowledge of the late effects of TBI.  By building 
upon existing clinical data collection infrastructure from ongoing longitudinal studies of 
individuals with TBI, the LETBI study aims to make inferences about possible post-traumatic 
neurodegenerative pathogenesis in individuals with remote injuries and enable identification of 
in vivo signatures of autopsy-confirmed neuropathology.  
The central hypothesis of the LETBI project is that TBI is associated with pathologic 
abnormalities detectable by neuropathological analyses that correlate with ultra-high resolution 
  
ex vivo magnetic resonance imaging (MRI) biomarkers, in vivo MRI biomarkers, and with 
neurobehavioral phenotypes.  We designed the LETBI project’s protocols to test this hypothesis, 
and to facilitate discovery science and hypothesis generation.   
 
Methods 
Study design: Overview 
Patients are screened for prospective enrollment in the LETBI project based on their 
participation in ongoing cohort studies led by the investigative team, including the Adult 
Changes in Thought (ACT) study, the TBI Model Systems (TBIMS), and the TBI-Health study.  
The ACT study has been continuously funded by the National Institutes of Health (NIH) 
since 1994 and includes volunteers from a random sample of community-dwelling non-demented 
Kaiser Permanente Washington (formerly Group Health) members over age 65 who are followed 
on a 2-year cycle to identify incident dementia cases.9 To date the study has enrolled >5,400 
people, approximately one quarter of whom have signed autopsy consents. ACT data sources 
include genome-wide single nucleotide polymorphism data, computerized pharmacy, clinical 
laboratory, and medical record data.  At baseline and each study visit, TBI exposure history is 
queried using standardized methods, and decades of medical records for ACT participants are 
available to characterize medical care received for TBI.  
The TBIMS is funded by the National Institute on Disability, Independent Living and 
Rehabilitation Research (NIDILRR).  This prospective study enrolls individuals with 
complicated mild-to-severe TBI at the time of inpatient rehabilitation, collecting extensive 
clinical and functional metrics with which to characterize the index TBI, and follows them at 1, 
  
2, and 5 years post-injury and every 5 years thereafter.10  The LETBI study recruits participants 
from two TBIMS centers. The Brain Injury Research Center at Mount Sinai (BIRC-MS), first 
funded in 1987, and the University of Washington (UW) TBIMS, first funded in 1998.  
The TBI-Health study in the BIRC-MS was funded by the Centers for Disease Control 
and Prevention (CDC) in 2012 and enrolls individuals who are at least one year post-
hospitalization for TBI.  The TBI-Health study gathers uniform metrics and medical record data   
to characterize the index TBI, and participants are followed biannually to gather 
neuropsychological data, self-report measures of mood and health, and clinician and caregiver 
ratings of behavior and function.  
 
Recruitment and eligibility criteria 
Individuals in the aforementioned studies are invited to participate in LETBI if they meet 
at least one of the following inclusion criteria: (1) history of complicated mild, moderate or 
severe TBI defined as a blow to the head resulting in at least one of the following: Glasgow 
Coma Scale score <13 on emergency department admission, loss of consciousness (LOC) >30 
minutes, post-traumatic amnesia >24 hours, or trauma-related intracranial abnormality on 
neuroimaging, or (2) history of 2 or more mild TBIs defined as an external blow to the head that 
results in physiological disruption of brain function or altered mental status; LOC if present is 
<30 minutes, post-traumatic amnesia if present is <24 hours, and Glasgow Coma Scale score 
≥13.11  LETBI enrollment began in 2014, with a goal of recruiting a convenience sample of at 
least 100 participants. Many survivors of TBI have contraindications to MRI due to implanted 
hardware and metallic devices, so those who are unable to complete in vivo MRI are included in 
  
the study to ensure that the LETBI cohort is representative of the population of interest. Only 
individuals who assent/consent to brain donation are enrolled in the LETBI project. Informed 
consent to participate in the LETBI project is obtained from the participant, or from his/her 
surrogate if he/she is unable to provide informed consent.  Control brain specimens from 
individuals with no history of TBI or neurological or psychiatric disease and no abnormalities 
detected on gross pathological analysis are acquired from patients who come to autopsy through 
partner studies at LETBI sites (UW, Mount Sinai, Brigham and Women’s Hospital and 
Massachusetts General Hospital [BWH/MGH]), with informed consent provided by the patient 
or his/her surrogate.  Control brains only undergo the ex vivo protocols described below.   
 
Neurobehavioral evaluation 
An overview of study procedures is shown in Fig. 1. All participants undergo a 
standardized neurobehavioral evaluation, which includes a battery of NIH Common Data 
Elements (CDEs).12 Neuropsychological tests measure attention, working memory, processing 
speed, verbal fluency, and visuo-motor sequencing. LETBI investigators assess motor symptoms 
and functional independence, and patients provide self-reported measures of mood and function. 
A summary of these assessments is provided in Table 1.  
  
Proteomic and genomic studies 
  A blood sample is drawn and prepared for proteomic and genomic analysis. Remaining 
plasma and serum are isolated and banked for future planned studies. Blood processing and 
storage protocols are harmonized with those of the NINDS-funded TRACK-TBI study.13 
  
 
In vivo MRI acquisition 
 Brain MRI is performed within a week of cognitive and behavioral assessments. Patients 
at Mount Sinai are scanned using a Siemens Skyra (Siemens Medical Solutions, Erlangen, 
Germany) 3 Tesla (T) MRI scanner with a 32-channel head coil for signal reception.  Patients at 
UW are scanned using a Philips Achieva 3T MRI scanner with a 32-channel head coil.  To 
facilitate pooling of MRI data from Mount Sinai and UW, we developed a harmonized protocol 
of high-resolution structural and functional sequences with only minor variances in the imaging 
parameters across sites (Supplementary Table 1).  The LETBI in vivo MRI protocol includes T1 
multi-echo MPRAGE (MEMPRAGE) for volumetric analyses,14 susceptibility weighted imaging 
for detection of traumatic microhemorrhages,15 diffusion MRI for tractography-based structural 
connectivity analysis,16, 17 and resting state functional MRI (rs-fMRI) for functional connectivity 
analysis.18  Sequence selection for LETBI was designed to maximize consistency with the NIH 
CDEs for TBI Neuroimaging.19, 20  
 
In vivo MRI processing and analysis 
In vivo MEMPRAGE and diffusion MRI data undergo a series of Freesurfer-based processing 
procedures, as previously described.14, 21  MEMPRAGE data are used to generate cortical and 
subcortical morphometrics, while diffusion data are used to measure anisotropy and diffusivity in 
white matter tracts. Resting-state fMRI data are processed using independent component 
analysis22 and seed-based analysis to measure functional network connectivity.23  
  
Each in vivo dataset is also assessed for pathoanatomic lesions, which are classified using 
the NIH CDEs for TBI Neuroimaging24 and, if applicable, NIH CDEs for Stroke 
Neuroimaging25.  These classification systems are similarly applied during the ex vivo MRI 
lesion analysis, allowing correlation of the in vivo and ex vivo lesion data.  Importantly, a second 
analysis of the in vivo MRI data is performed for participants who come to autopsy and undergo 
ex vivo MRI.  The ex vivo MRI data are co-registered to the in vivo MRI data (see below), 
providing an opportunity to assess the in vivo MRI signal properties at the precise spatial 
coordinates where the ex vivo MRI lesions are identified. Specifically, the ex vivo MRI data are 
used to identify lesions that escaped detection during the initial review of in vivo MRI data.   
 
Longitudinal follow-up 
All participants in the LETBI project agree to brain donation, and participants are 
encouraged to discuss their wishes with family members and significant others. The study team 
provides participants and their families with information about brain donation, in addition to 
detailed instructions to follow in the event of death. The study team contacts participants every 
6-9 months via telephone and sends holiday and birthday cards to maintain updated contact 
information.  
 
Verbal autopsy 
 Participants in the LETBI study are asked to provide contact information for at least two 
informants who know them well and who may be willing to participate in an interview in the 
event of death of the participant. The purpose of this postmortem interview is to gather 
  
information about the participant’s cognitive, motor, emotional and medical health in the year(s) 
prior to death. This information supplements data gathered through study visits and medical 
record review, including TBI exposure as ascertained by the Brain Injury Screening 
Questionnaire.26   
 
Brain specimen acquisition and neuropathological protocol  
For specimens obtained at UW, a prosector obtains the brain specimen and a rapid 
autopsy, consisting of dissection of one hemisphere for ~60 flash frozen specimens, is performed 
in cases with postmortem interval (PMI) < 8 hours. The remaining portion of the dissected 
hemisphere (or one intact hemisphere in non-rapid autopsies) is fixed in 10% formalin prior to 
undergoing comprehensive sampling and analysis for pathologic changes of AD, Lewy body 
disease, vascular disease, TBI, hippocampal sclerosis, frontotemporal lobar degeneration, etc. 
according to ACT protocols aligned with the latest diagnostic guidelines.27-31 In selected fixed 
tissues, Histelide analysis is performed for quantitative, molecularly specific analyses of 
pathologic peptides including phospho-tau species (see below).32, 33  The contralateral 
hemisphere from every case is fixed in 10% formalin and sent to BWH/MGH for gross 
pathological analysis and further fixation. For specimens obtained at Mount Sinai, whole brains 
are fixed in 10% formalin and sent to BWH/MGH for ex vivo MRI.  To ensure adequate fixation 
and to prevent specimen flattening (which can prevent specimens from fitting into custom ex 
vivo MRI coils and can distort the MRI data), we implemented a series of standard procedures 
for optimal brain fixation and specimen processing, as detailed in the Supplementary Material.   
 
  
Histopathological analysis: Histelide 
The steps involved in Histelide analysis are detailed elsewhere32, 33 and in the 
Supplementary Methods.  
 
Ex vivo MRI acquisition 
Ex vivo MRI is performed on selected autopsy brain specimens that meet the following a 
priori selection criteria: 1) postmortem fixation interval (time from death to fixation of the 
specimen) < 48 hours; 2) availability of comprehensive, prospectively acquired cognitive and 
behavioral data; and 3) availability of in vivo MRI data acquired prospectively with the LETBI 
protocol.  Each ex vivo MRI sequence was designed to provide complementary information 
about post-traumatic dementia pathology and to create opportunities to identify novel MRI 
biomarkers.  Each ex vivo MRI sequence also provides unique tissue contrast and signal 
characteristics that correspond to those of an in vivo MRI sequence, as shown in Supplementary 
Table 2.   
Brain specimens are first scanned on a 7T Siemens Magnetom MRI scanner using a 
custom-built head coil.  The design, technical specifications, and signal-to-noise-ratio 
evaluations of the coil are detailed in the Supplementary Methods.  For the 7T scan, we utilized a 
multi-echo FLASH (MEF) sequence34 at 200 µm spatial resolution. Total scan time on the 7T 
MRI scanner is 18 hours and 31 minutes. Next, specimens are scanned on a 3T Siemens Tim 
Trio MRI scanner for 41 hours and 45 minutes using a 32-channel head coil. MEF data are also 
collected at 3T at 1 mm spatial resolution for generating surface reconstructions. Diffusion data 
are acquired using a 3D diffusion-weighted steady-state free-precession (DW-SSFP) sequence35 
  
at 750 µm spatial resolution.  Total diffusion scan time is 30 hours and 31 minutes. Parameters 
for all 7T and 3T ex vivo sequences are detailed in Supplementary Table 3.  
 
Ex vivo MRI processing and analysis 
MEF data acquired on the 7T and 3T MRI scanners undergo a series of processing steps, 
including creation of parameter maps.  Parameter maps include proton density and T1 and T2* 
decay times. These are estimated directly from the MEF acquisitions using the DESPOT1 
algorithm34, 36 to quantify the tissue properties independent of the scanner and sequence types. 
We use our surface-based registration and segmentation tool, FreeSurfer,37, 38 to reconstruct 
models of the gray/white and pial surfaces for morphometric analysis of the 3T MEF data.  Upon 
completion of data processing, each 7T and 3T MEF dataset is assessed for data quality based 
upon a visual assessment of anatomic landmarks.  If the data are deemed to be of sufficient 
quality, the MEF datasets are then analyzed by LETBI investigators for pathoanatomic lesions in 
two phases.   
In the first phase of ex vivo MRI data analysis, the 7T and 3T MEF datasets are assessed 
for pathoanatomic lesions that can be classified using the NIH CDE Guidelines for TBI and 
Stroke Neuroimaging.19, 25  In the second phase, we assess for pathoanatomic lesions that are not 
currently accounted for by the NIH CDE criteria, which were generated for in vivo MRI lesion 
characterization.  In this second phase, lesions identified on the 7T and 3T MEF datasets are 
classified based upon their signal characteristics, neuroanatomic location, and morphology.   
 Diffusion data acquired on the 3T MRI scanner are processed for deterministic tract 
construction using Diffusion Toolkit and analyzed for connectivity using TrackVis 
  
(www.trackvis.org), as previously described.39 All major association, projection, and 
commissural white matter bundles in the cerebral hemispheres are analyzed for structural 
connectivity using the ROI approach described in Catani and de Schotten’s tractography atlas.40  
In addition to the white matter bundles described in this atlas, thalamocortical tracts are 
identified using a single-ROI approach41 and brainstem arousal pathways are identified using a 
multi-ROI approach.42, 43  All tract bundles are inspected for hemispheric asymmetry and/or focal 
disruptions, as compared to a cohort of control brain specimens from patients who died of non-
neurological diseases and had no known history of trauma.  In addition, any lesion identified 
during the ex vivo MRI lesion analysis is used as a seed for the generation of fiber tracts. Using 
this seed-based lesional approach, the pathophysiological impact of each lesion on its associated 
white matter pathways are defined.   Ex vivo MRI acquisition and processing methods are 
identical for control and TBI specimens.    
In summary, the ex vivo MRI analyses provide four sets of data that are subsequently 
correlated with histopathological and in vivo MRI data: 1) NIH CDE-based lesion analysis of 7T 
and 3T MEF data; 2) analysis of lesions detected by 7T and 3T MEF data that are not currently 
accounted for by the NIH CDEs; 3) 3T diffusion tractography analysis of white matter disruption 
via screening of all major white matter bundles; and 4) 3T diffusion tractography analysis of 
white matter disruption related to focal lesions.  
 
Co-registration of in vivo MRI and ex vivo MRI data 
We used the combined volume- and surface-based registration (CVS) framework44 to 
spatially register the corresponding in vivo and ex vivo MRI datasets. CVS is a pair-wise 
  
registration method that has been shown to optimize the alignment of both cortical and 
subcortical areas in brain volumetric MRI. Additional details are provided in the Supplementary 
Methods.  
 
MRI-guided brain cutting, imaging-pathology procedures, whole mount immunohistopathology 
 Following ex vivo MRI of fixed hemibrain and whole brain specimens, ACT brains are 
shipped from MGH/BWH to the UW Neuropathology and Targeted Molecular Testing Core, and 
TBIMS/TBI-Health brains are shipped to the Brain Tissue Repository (BTR) and 
Neuropathology Core of the Center for Neuroscience & Regenerative Medicine (CNRM), at 
USUHS in Bethesda, MD.45  Slabs are selected at both institutions (see below) for whole mount 
sectioning, neuropathologic assessment using routine morphologic stains, 
immunohistochemistry, histochemistry for myelin and iron, and image digitalization of the 
resultant slides.  Each specimen is sectioned into 3 parts: the cerebral hemisphere(s), brainstem, 
and cerebellum.  The hemisphere specimens are sectioned coronally and photographed to obtain 
an overview of brain structures within hemisphere(s) in both projections: rostral (frontal) and 
caudal (occipital).  Slabs are then selected for whole mount analysis during a consensus video 
teleconference in which the neuropathology team and imaging team compare cortical and 
subcortical anatomic landmarks on the coronal slabs with corresponding landmarks on the ex 
vivo MRI datasets.  Based on this landmark comparison, the precise neuroanatomic coordinates 
of each lesion identified on ex vivo MRI is used to guide the selection of the corresponding 
coronal slab.  
  
Coronal slabs are embedded in oversized paraffin blocks and serially sectioned at 50 μm 
thickness. For ACT cases, unselected slabs undergo routine neuropathological analysis to 
maintain continuity of neuropathological data for the ACT study. For slabs selected for whole 
mount analysis, the level of sectioning within each block is guided by identification of lesions on 
ex vivo MRI acquisition. With an interval of 200 sections (1 cm), we cut 10 serial sections, at 10 
microns thick, to be stained for hematoxylin and eosin (H/E), Luxol-fast Blue (LFB), Perls’ stain 
(iron), hyperphosphorylated-tau (pTau; AT8), phosphorylated α-synuclein (pα-syn), amyloid 
precursor protein (APP), 1-42 β-amyloid (4G8), phosphorylated-TAR DNA-binding protein 43 
(pTDP-43), glial fibrillary acidic protein (GFAP), and activated microglia (CD68 and iba-1). 
When indicated, we obtain ~20 levels through the entire hemisphere to survey the full 
distribution of pathology. The separated brainstem specimen is sectioned in the axial plane to 
obtain 4 tissue blocks. Each block is then embedded, serially sectioned and stained, as described 
previously,42 or saved for future analyses. The cerebellum is saved for future analysis.   
 
Consensus conferences for validation of neuropathology and imaging biomarkers 
We use VS NIS-SQL software to allow real-time on-line simultaneous viewing of 
scanned whole-mount slides at each study site. Conference goals are to correlate 
neuropathological findings with study records, clinical data, in vivo MRI and ex vivo MRI. 
Digitized slides are also viewed and discussed in this forum. This is an opportunity to regularly 
assemble an expert panel to consider histopathologic and other endpoints to achieve meaningful 
associations and identify effective diagnostic approaches.  
 
  
Results 
Enrollment summary 
As of September 2017, 158 individuals with TBI have enrolled in the LETBI study, all of 
whom consented to brain donation. A subsample of 105 participants completed in vivo MRI. 
Those with contraindications to MRI, including implanted devices that were MRI incompatible, 
were excluded.  Those with claustrophobia or MRI-safe devices that caused substantial artifact 
did not complete the MRI scan. Thus far, eight individuals have come to autopsy.  All eight 
brains have been successfully acquired by the LETBI study team, and to date six have undergone 
ex vivo MRI; data analysis and interpretation is ongoing.   
 
Index case: Demographic and clinical data 
Here we use data collected from the first participant to complete the ex vivo LETBI 
protocol to illustrate the LETBI study methods and data integration protocols. This individual is 
a right-handed female with a high school education who lived independently in a senior 
apartment until death around age 90. She enrolled in the ACT study in her late 60s, reporting no 
chronic medical conditions, but her history was notable for TBI. Her lifetime exposure to TBI is 
summarized in Table 2. 
 
Cognitive and Functional data 
Our index case completed the LETBI neurobehavioral protocol in her mid-80s (after her 
first two TBIs, which occurred >60 years and 4 years prior, respectively). She performed well on 
this comprehensive battery of cognitive tests. Based on this evaluation, she was given the clinical 
  
diagnosis “normal cognition.” On the Uniform Parkinson’s Disease Rating Scale motor 
examination, her right leg agility could not be assessed, her ability to rise from a chair was 
“slow, or may need more than one attempt,” her posture was “not quite erect, slightly stooped” 
and her gait was normal but notable for “retropulsion, but recovers unaided.” She reported no 
neurobehavioral or mood symptoms and reported no difficulties on the Functional Assessment 
Questionnaire. 
The patient participated in ACT study visits every 2 years from her late 60s to death (11 
visits total).  She described her health as “good” or “very good” at all ACT study visits. She was 
consistently overweight (body mass index = 25-30) and was diagnosed with hypertension and 
sleep apnea in her early 80s. Her APOE genotype was 2/3, and she reported no family history 
of dementia. She consistently reported exercising at least 15 minutes every day, until her last 
study visit when she indicated her exercise was reduced to 4 days per week.  She reported no 
difficulty with activities of daily living including bathing, dressing, feeding, toileting, or walking 
until age 83 when she had “some difficulty” getting out of a bed or a chair, and by age 89 
reported “a lot of difficulty” with these activities. Her balance was not assessed at her last study 
visit, but at age 87 she was only able to perform a semi-tandem (as opposed to full tandem) walk. 
   
In vivo MRI: NIH Common Data Elements assessment 
3T MRI was performed at age 88, after her 5th TBI.  The T2 fluid-attenuated inversion 
recovery (FLAIR) sequence revealed two pathoanatomic lesions: lesion 1, punctate 
hyperintensities in the corona radiatae and internal capsules of both hemispheres (Fig. 2 and 
Supplementary Fig. 1); and lesion 2, bilateral periventricular hyperintensities (Supplementary 
  
Fig. 1; Supplementary Table 4).  These lesions were classified using the NIH Common Data 
Elements for TBI Neuroimaging and Stroke Neuroimaging as being consistent with leukoaraiosis 
or possibly chronic traumatic axonal injury (Supplementary Table 4). 
 
Cause of death 
Following her 6th documented TBI (see Table 2), a head computed tomography scan 
demonstrated a right parietal subdural hemorrhage with subfalcine herniation and 1.1 cm of 
right-to-left midline shift at the level of the septum pellucidum.  She underwent craniotomy for 
evacuation of the subdural hemorrhage and recovered well over the following week.  She was 
transferred to a subacute nursing facility for rehabilitation, but she then experienced an episode 
of high blood pressure, slurred speech and facial drooping, for which she was readmitted to 
hospital.  She experienced several similar episodes while in the hospital, as well as episodes of 
expressive aphasia and delirium.  No definitive etiology of these transient events was determined 
despite diagnostic evaluation.  Her clinical condition deteriorated, necessitating surgical 
placement of a percutaneous gastric tube, which was contrary to her previously documented 
wishes. She was therefore transferred to hospice care and died approximately one month after 
her injury.  
 
Gross pathological analysis 
At autopsy, the patient’s brain weighed 1,280 grams (unfixed) and postmortem interval to brain 
fixation was 4 hours.  There was no evidence of mass lesions, destructive lesions, or herniation. 
There was mild cortical atrophy involving the frontal, temporal, and parietal lobes; occipital 
  
lobes were relatively spared. Surface analysis of the gross, unfixed brain specimen revealed 
golden discoloration of the right inferior frontal gyrus and superior temporal gyrus, suggesting 
hemosiderin deposition from previous subarachnoid hemorrhage (Supplementary Fig. 2). Gross 
examination for other focal lesions was negative in the sliced brain (after ex vivo imaging studies 
were completed).  
 
Ex vivo 7 Tesla MRI 
7T MRI quality assessment revealed excellent delineation of anatomic landmarks 
(Supplementary Fig. 3) and minimal distortions related to air bubbles.  In the first phase of ex 
vivo MRI lesion analysis, we observed the same two lesions seen on in vivo MRI: punctate 
hyperintensities in the corona radiata and internal capsule (lesion 1, Fig. 2) and periventricular 
hyperintensities – (lesion 2, Figs. 3, 4A). A summary of the NIH Common Data Element 
analysis for ex vivo MRI is provided in Supplementary Table 5.  During the second phase of ex 
vivo MRI lesion analysis, we identified a third and fourth abnormality.  Lesion 3 was a 
curvilinear lesion that followed the outline of the superficial cortex in the frontal operculum 
(Figs. 3, 5). Lesion 4 was a focal, well-circumscribed lesion in the occipital white matter, 
posterolateral to occipital horn of lateral ventricle (Fig. 3).  
  
Ex vivo 3 Tesla MRI 
Tractography analysis of the major association, projection, and commissural white matter 
bundles revealed a fifth lesion: a focal decrease in the relative density of reconstructed fiber 
tracts in the parietal region of the corpus callosum.  Lesion 5 is best illustrated when compared to 
  
the corresponding region of fiber tracts in a control dataset from a 60-year-old woman who died 
of non-neurological causes (Fig. 6). The density of fiber tracts visualized in other white matter 
bundles, such as the corticospinal tract and cingulum bundle, was similar to those of the control 
dataset (Supplementary Figs. 4, 5), indicating that the callosal tract abnormality did not represent 
global tract loss.  The lesion-based tractography analysis revealed that lesion 5 caused minimal 
tract disruption within the inferior longitudinal fasciculus and the inferior fronto-occipital 
fasciculus (Supplementary Fig. 6), which is consistent with the patient’s high-level performance 
on tests of associated cognitive functions such as memory and attention.   
 
Integration of ex vivo MRI and in vivo MRI 
CVS-based co-registration was performed to align the ex vivo 7T MEF and in vivo 3T T1 
MEMPRAGE datasets (Fig. 7). Once anatomic alignment was confirmed, the precise anatomic 
coordinates of the occipital lesion, as detected on the ex vivo 7T MEF dataset, were identified on 
the in vivo 3T T1 MEMPRAGE dataset.  At these coordinates, a hypointense focus was observed 
on the in vivo 3T T1 MEMPRAGE dataset taken after her 5th TBI, 2 years prior to death (Fig. 8).  
Notably, this hypointense focus was not identified as a lesion during the in vivo CDE analysis 
performed by our research team.   
 
Histopathological analysis 
Standard histopathological analyses, performed blind to MRI findings, revealed phospho-
tau immunoreactive neurofibrillary tangles in pre-alpha cells of the transentorhinal cortex, CA1 
sector of hippocampus, and subiculum, but absent in other sectors of hippocampus, entorhinal 
  
cortex, isocortex, primary sensory cortex or granule neurons of dentate fascia (Braak stage III). 
Aβ neuritic or diffuse plaques as determined by Bielschowsky and Aβ immunostains (4G8) were 
absent in neocortex, isocortex, hippocampus, striatum, midbrain, and cerebellum indicating a 
Thal phase 0 of 5 for β-amyloid distribution.46 Cerebral amyloid angiopathy was absent. Cortical 
Lewy bodies were evaluated by H/E stain and by α-synuclein immunohistochemistry and were 
absent in all regions examined. Moderate arteriolosclerosis was present in sections of neocortex 
and deep gray matter. Microvascular brain injury was absent, and chronic infarcts were not 
identified. Hippocampal sclerosis was not identified, and phospho-TDP-43 pathology was absent 
in hippocampus and in the entorhinal/medial temporal cortex. Together, these findings suggest 
no evidence of pathological processes of AD, Lewy body disease, frontotemporal dementia, or 
vascular brain injury. The presence of neurofibrillary tangles in hippocampus in the absence of 
ß-amyloid pathology indicates definite primary age-related tauopathy (PART), which is often 
seen in the absence of clinical dementia or MCI.47 
 In the MRI-guided histopathological analysis, focal lesions identified on in vivo and ex 
vivo MRI were evaluated for their histopathological correlates. Within the periventricular white 
matter lesion (lesion 2), histopathological analysis revealed moderate numbers of granular to 
linear APP-immunoreactive axonal profiles adjacent to a medium-sized parenchymal vessel (Fig. 
4C).  The degree to which chronic microvascular disease versus chronic TAI contributed to the 
pathogenesis of this axonal pathology cannot be definitively determined, but the periventricular 
and perivascular location is consistent with a vascular etiology.  For the curvilinear cortical 
lesion (Fig. 3, lesion 3), histopathological analysis revealed cortical gliosis associated with 
numerous hemosiderin-containing microglia (Perls’ positive) and neuronal loss consistent with a 
  
healed contusion (Fig. 5). In addition, histopathological examination of nearby cortex in the 
frontal operculum revealed phospho-tau deposition, as well as APP-immunoreactive axons in the 
underlying white matter (Supplementary Fig. 7).   
 
Whole mount analysis 
For this case we selected a slab for whole mount analysis based upon its correspondence with the 
coronal region that contained lesion 4 (Fig. 9).  Whole mount analysis using hematoxylin and 
eosin, Perls’ iron and LFB/cresyl violet myelin stains revealed neuroanatomical features directly 
comparable to those seen in the ex vivo MRI dataset.  Specifically, histopathological analysis 
revealed enlarged perivascular spaces, corpora amylacea, and white matter rarefaction (Fig. 9D), 
all of which are likely attributable to chronic ischemic injury.  The white matter rarefaction had 
the greatest dimension, making it the most likely histopathological correlate for the ~2 mm 
diameter MRI lesion.  Immunohistochemistry for phosphorylated tau revealed no evidence of 
CTE neuropathology in routine, whole mount, or image-guided histopathological analyses. 
 
Discussion 
The LETBI project represents a systematic effort to characterize the clinical and pathological late 
effects of TBI with the goal of identifying in vivo signatures of postmortem pathology.  This 
multimodal approach to integrating histopathology, ex vivo MRI, in vivo MRI, and cognitive-
behavioral data in the LETBI project is based upon the premise that postmortem 
neuropathological data in well-characterized clinical samples are essential to elucidate the 
pathogenesis of post-TBI neurodegeneration, define relationships between TBI neuropathology 
  
and clinical phenotypes of commonly diagnosed neurodegenerative conditions, identify risk 
factors, and develop diagnostic and therapeutic strategies.  Here we describe the study methods 
and demonstrate feasibility and proof of concept using data collected from the first participant to 
undergo our full ex vivo protocol.  This unselected case demonstrates the utility of this approach 
to characterizing the late effects of TBI even in a patient who had normal cognition and 
functional independence until her early 80s after sustaining two TBIs with LOC. Our methods 
are well suited to accommodate the complexity of distinguishing the late effects of TBI in older 
adults, in whom pathological abnormalities are the norm rather than the exception, and in whom 
the links between pathological abnormalities and clinical manifestations is much weaker than it 
is among younger individuals. As the LETBI sample grows, our unbiased case selection and 
comprehensive in vivo and ex vivo characterization may facilitate identification of markers of 
resilience to the late effects of TBI, which in turn may inform treatment strategies. 
 An innovation in the LETBI project is the acquisition of ex vivo MRI data to serve as a 
methodological bridge linking gold-standard histopathological data to in vivo MRI and 
cognitive-behavioral data.  As seen in our index case, ex vivo MRI is able to detect lesions not 
seen by in vivo MRI, and provides a 3-dimensional whole-brain view of pathological lesions not 
sampled during a histopathological evaluation. Identification of lesions on ex vivo MRI enables 
targeted histopathological sampling of the brain tissue. Similarly, advanced ex vivo-to-in vivo 
MRI co-registration technique allow precise localization of the neuroanatomic coordinates of a 
lesion on the in vivo MRI dataset, enabling analysis of its in vivo MRI signal characteristics and 
its clinical correlates. The approach presented here thus represents an opportunity to link the 
microscope to the bedside using ex vivo MRI as an intermediate.   
  
 The LETBI project also aims to balance the complementary approaches of hypothesis 
testing and hypothesis generation. We designed the study to accommodate the need for 
prospective, unbiased analyses that control for exposures that may confound the association 
between TBI and neurodegeneration (e.g. substance abuse), while fully recognizing that current 
knowledge about the in vivo biomarkers and histopathological signatures of post-traumatic 
neurodegeneration is insufficient.  Given recent evidence that post-traumatic neurodegeneration 
may be a polypathology4, 6 with histopathological features of AD, PD, CTE, and vascular lesions, 
we designed the LETBI project to allow for the identification of different types of pathologies.  
Specifically, the ex vivo MRI protocol involves multiple contrasts, and the histopathological 
protocol involves multiple immunostains.  The importance of this balanced approach to 
hypothesis testing and hypothesis generation is evidenced by the results from the index case. On 
the one hand, the results of the occipital lesion analysis support the hypothesis that TBI is 
associated with pathologic abnormalities that correlate with ultra-high resolution ex vivo MRI 
biomarkers and in vivo MRI biomarkers.  On the other hand, the absence of clinical signs of 
dementia and the absence of pathological features of neurodegeneration despite six TBIs provide 
a basis to test future hypotheses about mechanisms of resiliency to post-traumatic 
neurodegeneration. 
 Importantly, participants in the LETBI Project have a history of TBI, but do not 
necessarily have clinically significant deficits or evidence of decline. Enrollment of patients prior 
to symptom onset allows us to comprehensively characterize at-risk individuals before the onset 
of late effects of TBI. Although many long-term survivors of TBI experience dramatic functional 
decline from a previously achieved level of recovery, others remain stable or even continue to 
  
recover for years after injury.48 As seen in the index case reported here, a history of multiple 
injuries sustained across the lifespan does not preclude high level functioning into late life and 
minimal postmortem evidence of traumatic injury. Our choice to demonstrate the LETBI project 
methods using this case, the first to undergo the full LETBI ex vivo protocol, is consistent with 
the LETBI investigative team’s commitment to share positive and negative findings with equal 
transparency in an effort to fully elucidate the late effects of TBI. 
 There are several limitations to the LETBI study that warrant consideration.  First, while 
the prospective enrollment of at-risk, asymptomatic individuals with prior TBI reduces selection 
bias, this approach also necessitates a larger sample size and longer duration of follow-up to 
make robust inferences about mechanistic links between TBI and neurodegeneration.  Other 
studies have made major contributions to characterizing post-traumatic pathology by gathering 
postmortem brain specimens from symptomatic individuals with specific types of TBI exposure 
(e.g. athletes with repetitive head trauma).49 The LETBI study similarly aims to characterize 
post-traumatic neuropathology, but the complementary goal of identifying in vivo markers of this 
pathology necessitates a concerted long-term effort for prospective clinical data collection. 
Relatedly, early hypothesis testing will be restricted to analyses that are appropriately powered as 
the sample size grows with continued enrollment.  Second, the control cases in the LETBI study 
undergo only the ex vivo MRI and histopathology protocols, and comprehensive clinical data are 
not routinely available, . which may introduce a potential source of sampling biasThe control 
cases also originate from separate cohorts, which introduces a potential source of sampling bias. 
Third, the LETBI study does not leverage recent advances in structural and functional MRI.39, 50  
Like other ongoing multi-institutional TBI studies,13 the LETBI study prioritizes harmonization 
  
and standardization of in vivo MRI protocols across sites, recognizing that there is an inherent 
trade-off between standardization and innovation.    
 
Conclusions 
Postmortem data gathered from well-characterized clinical cohorts are essential to 
characterize the pathological substrate associated with the late effects of TBI and to determine 
the clinical signatures of post-TBI neurodegeneration. Prospective clinical studies with autopsy 
endpoints minimize selection bias and address the many factors that may impact associations 
between TBI exposure and neurodegenerative pathology.51 The methods described here are 
designed to advance scientific knowledge about the pathological substrates and clinical 
phenotypes associated with post-traumatic neurodegeneration and resilience, while also 
facilitating discovery of novel histopathological and neuroimaging biomarkers for future 
hypothesis testing. The LETBI project uses multimodal methods to link in vivo imaging and 
neurobehavioral data with ex vivo imaging and histology, with a goal of facilitating prevention, 
diagnosis and treatment of post-TBI neurodegeneration during life. 
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